Specialty vaccine company Valneva, along with Pfizer, reported positive Phase II data from their clinical trial evaluating a Lyme disease vaccine candidate.

BioSpace reviewed some of the more interesting scientific studies recently published, including research into a potential cause of Alzheimer’s disease and how deleting dysfunctional fat cells could alleviate diabetes.

The U.S. Food and Drug Administration approved Pfizer’s tick-borne encephalitis vaccine TICOVAC to prevent TBE in people aged 1 year and older.

With Lyme disease season emerging and the Covid-19 pandemic still with us, an important webinar designed to help physicians differentiate between the two (as well as the flu) so as to provide timely diagnosis and treatment for their patients will be held on Wednesday, May 5. The webinar is the latest in an ongoing series sponsored by Quidel, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions.

The U.S. Food and Drug Administration accepted for Priority Review Pfizer Inc.’s Biologics License Application for TicoVac, the company’s tick-borne encephalitis vaccine for active immunization to prevent TBE in individuals 1 year of age and older.

  While most of us are concerned about Lyme disease, a tickborne illness circulating during the spring and summertime in the Northeastern U.S, there is another, potentially more serious infection […]